<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194971</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00017446</org_study_id>
    <nct_id>NCT03194971</nct_id>
  </id_info>
  <brief_title>NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy</brief_title>
  <official_title>NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whole brain samples from glioblastoma patients at autopsy to determine&#xD;
      the underlying pathological signatures of tumor treatment fields at autopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE:&#xD;
&#xD;
      Optune therapy with tumor treatment fields (TTFields) has recently been FDA approved for the&#xD;
      treatment of newly diagnosed glioblastoma due to a recent clinical trial that showed&#xD;
      improvement in progression free survival and overall survival compared to standard therapy.&#xD;
      (1) TTFields also have a role in the recurrent glioblastoma treatment where it has&#xD;
      demonstrated equal efficacy to second-line chemotherapy also has been shown to tumor&#xD;
      progression and improve overall survival.(2) Though preclinical studies are ongoing,&#xD;
      glioblastoma patients who have undergone TTField therapy have not yet been assessed at&#xD;
      autopsy to determine both the pathological signature of TTField treatment, and the pattern of&#xD;
      failure. This study will determine how the underlying pathological signatures of tumors&#xD;
      treated with TTFields differ from those na√Øve to TTFields by comparing tumor tissue at&#xD;
      autopsy.&#xD;
&#xD;
      STUDY:&#xD;
&#xD;
      All patients undergoing TTField therapy for newly diagnosed and recurrent glioblastoma will&#xD;
      be considered for inclusion for this study. The investigators expect to enroll five patients&#xD;
      per year for four years, totaling 10 patients treated upfront and 10 patients treated at&#xD;
      tumor recurrence. An objective of this study is to determine differences in the pathological&#xD;
      pattern of failure when patients are treated with TTFields at initial diagnosis (up-front)&#xD;
      compared to those treated at tumor recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of mitotically active cells</measure>
    <time_frame>At baseline</time_frame>
    <description>Tissue samples will be obtained at autopsy and stained for KI-67. Slides will then be digitized, and the number of active cells will be counted computationally.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of mitotically inactive cells</measure>
    <time_frame>At baseline</time_frame>
    <description>Tissue samples will be obtained at autopsy and stained for KI-67. Slides will then be digitized, and the number of not active cells will be counted computationally.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitotic Ratio</measure>
    <time_frame>At baseline</time_frame>
    <description>Number of mitotically active cells divided by the number of not mitotically active cells per patient will be calculated.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>TTField at Recurrence</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>TTField at New Diagnosis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor samples from patients treated with TTFields at initial diagnosis.</intervention_name>
    <description>Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.</description>
    <arm_group_label>TTField at New Diagnosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tumor samples from patients treated with TTFields at tumor recurrence.</intervention_name>
    <description>Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.</description>
    <arm_group_label>TTField at Recurrence</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples are obtained from regions suspicious for tumor at autopsy.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly Diagnosed Glioblastoma Patients undergoing standard of care treatment consisting of&#xD;
        surgery followed by chemo-radiation therapy will have the addition of Optune TTField&#xD;
        therapy together with adjuvant chemotherapy. OR Recurrent Glioblastoma Patients with&#xD;
        glioblastoma tumor recurrence defined by either imaging criteria, or deteriorating&#xD;
        neurological function will be offered Optune TTField treatment at the discretion of the&#xD;
        neurooncologist.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed glioblastoma, World Health Organization (WHO) grade IV, patients&#xD;
             undergoing TTField therapy.&#xD;
&#xD;
          -  Recurrent glioblastoma WHO grade IV, patients undergoing TTField therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TTField compliance &lt; 75%.&#xD;
&#xD;
          -  Any contraindication to Optune TTField treatment.&#xD;
&#xD;
          -  Initial brain tumor diagnosis &lt; WHO grade IV.&#xD;
&#xD;
          -  Duration of TTField therapy &lt; 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter LaViolette, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical College of Wisconsin Cancer Center Clinical Trials Office</last_name>
    <phone>414-805-8900</phone>
    <email>cccto@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Froedtert &amp; the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter LaViolette</last_name>
      <phone>414-456-7490</phone>
      <email>plaviole@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Peter LaViolette</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>glioblastoma</keyword>
  <keyword>brain tumor autopsy</keyword>
  <keyword>autopsy</keyword>
  <keyword>Optune therapy</keyword>
  <keyword>tumor treatment fields</keyword>
  <keyword>TTFields</keyword>
  <keyword>Recurrent glioblastoma</keyword>
  <keyword>grade IV</keyword>
  <keyword>brain tumor</keyword>
  <keyword>newly diagnosed glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

